Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →A data-backed look at gastroretentive floating tablet buoyancy control patents: filing trends since 2015, leading assignees, technology composition across 260 records, and where claim white space remains open in 2026.
Filing growth = 2021 (18 records) → 2024 (12); 2024 is the last year we treat as complete. Top-5 share = the 5 largest assignees ÷ all 260 records in scope (CR5), not the ranked leaders only.
Gastroretentive floating tablets keep a dosage form in the stomach longer by controlling its density relative to gastric fluid, using one of three broad mechanisms: gas-generating systems, low-density polymer matrices, or osmotic-coated cores. Across the 260 records in scope, claim activity sits almost entirely in formulation chemistry rather than device engineering — 91.9% of records carry an A61K medicinal-preparation classification, and 40.4% tie the buoyancy mechanism to a specific therapeutic activity under A61P.
Filing activity rose through the late 2010s, peaked in 2019 at 23 records, and has since eased to 12 by 2024 — a 33% decline over the 2021-2024 span. China and India dominate receiving-office volume, consistent with generic and branded-generic manufacturers using floating-tablet formulations to extend existing drug franchises rather than filing platform patents from scratch.
Pick a task. Every answer cites the patents behind it.
Filing activity across the 260 records in scope shows a field that grew steadily through the late 2010s, peaked, and has since settled into a lower but still active baseline — with formulation chemistry, not device engineering, absorbing almost all the claim volume.
Filings rose from 11 in 2017 to a peak of 23 in 2019, then eased to 18 by 2021 and 12 by 2024 — a 33% decline over that three-year span. 2025 and 2026 figures are still incomplete because publication lags filing by roughly 18 months, so the most recent years understate actual activity.
Publication lags filing by roughly 18 months, so 2025 onwards are still filling in. Growth rates on this page therefore end at 2024; running them to the last bar would understate the field.
A61K (medicinal preparations) appears on 91.9% of the 260 records and A61P (therapeutic activity) on 40.4%, confirming this is overwhelmingly a formulation-chemistry field. Every other subclass — heterocyclic compounds, containers, food formulations, 3D printing, agrochemicals — sits at 2.3% or below, marking the thin branches around the formulation core.
Shares are the percentage of the 260 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
This page is one run against one query. Ask Eureka your own question about gastroretentive floating tablet buoyancy control patent landscape and every answer comes back with the patent numbers behind it.
Try EurekaThe present invention relates to an osmotic floating tablet comprising: (i) an inner core comprising a drug, one or more low density polymers, and one or more pharmaceutically acceptable excipients; and (ii) an outer osmotic coating surrounding the inner core that is substantially permeable to surrounding fluids and substantially impermeable to the drug. The present invention also relates to processes for the preparation of said tablets.Structural claim: low-density core plus asymmetrically permeable outer coating — a distinct architecture from gas-generating or matrix-only floating systems.
View full claim record| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US4216994A | Tablet side arm for chairs | 43 |
| 2 | CN104887641A | 帕布昔利布胃漂浮片及其制备方法 | 37 |
| 3 | CN103239482A | 一种美洲大蠊胃漂浮片及其制备方法和应用 | 23 |
| 4 | US20040115259A1 | Method for producing a floating tablet containing an active principle and the tablet obtained | 23 |
| 5 | US20010046473A1 | Gastric-retained pharmaceutical composition and method for its use | 23 |
| 6 | CN101011381A | 一种银杏内酯类药物的胃漂浮片及其制备方法 | 17 |
| 7 | WO2010143052A1 | Novel pharmaceutical compositions containing pregabalin | 16 |
| 8 | WO2020006278A1 | Self-regulating osmotic gastroretentive drug delivery systems | 13 |
| 9 | US20190175499A1 | Use of chlorogenic acid in preparing pharmaceuticals for treatment of LAG-3-mediated disease | 13 |
| 10 | JP2001158703A | Water face-floating tablet agrochemical composition for paddy field, method for using the same and method for… | 13 |
Citation counts favour older records within the searched corpus and should be read as a signal of influence, not current relevance.
Patent titles are shown in the language they were filed in, not translated, so that each record stays verifiable against the original filing — a translated title will not match in Eureka or in any national register. Each row carries its publication number; clicking a row searches Eureka by that number.
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →Three figures matter more than the raw record count: how concentrated ownership is, how the trend has moved since the 2019 peak, and where claim density thins out.
The leader holds 21 records and the top 10 combined hold 92 (35.4% of all 260 records), which is real concentration but not a chokehold — most of the field is a long tail of single- or few-filing entrants.
Filings peaked at 23 in 2019 and eased to 12 by 2024. 2024 is the last year with a complete publication record; 2025-2026 will fill in further as later-filed applications publish.
Medicinal-preparation claims (A61K) dominate at 91.9% of records; every non-pharmaceutical branch — 3D printing, food, agrochemical uses — sits at 1.5% or below.
China and India lead receiving-office volume by a wide margin over the US (28), EPO (14) and WIPO (12), consistent with generic and branded-generic manufacturers extending existing drug franchises.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to gastroretentive floating tablet buoyancy control patent landscape, with the prior art for and against each one.
The figures above set the boundaries of the field. The next questions are specific to what you are trying to file or clear.
If you are developing a floating tablet, compare its core-and-coating or core-and-gas-chamber architecture against the structural claims held by the ranked leaders, not just against compositional excipient claims.
Run a claim comparison in Eureka2025 and 2026 filings are still publishing. Revisit the trend once those years complete to see whether the 2021-2024 decline continues or levels off.
Set a filing alert in EurekaB33Y-classified floating tablet filings sit at just 1.5% of records. If additive manufacturing is part of your formulation strategy, this branch warrants a closer freedom-to-operate look.
Explore white space in EurekaA gastroretentive floating tablet is a dosage form designed to stay in the stomach longer than a standard tablet, usually by lowering its effective density below that of gastric fluid so it floats rather than passing through the pylorus. Buoyancy is achieved either by generating gas in situ (typically from a bicarbonate-acid reaction) that gets trapped in a swelling matrix, by building the tablet from inherently low-density polymers, or by combining a low-density core with an osmotically active outer coating. The choice of mechanism affects lag time before floating, duration of buoyancy, and how the formulation interacts with food and gastric pH, which is why the patent literature splits cleanly into these three mechanism families.
Filing is moderately concentrated: the ranked leaders' top 5 assignees together hold 23.1% of the 260 records in scope, and the top 10 hold 35.4%, with the single leader at 21 records. That leaves a substantial long tail of entrants with only one or two filings each, spread across pharmaceutical manufacturers, generic drug makers, and academic institutions. No single company holds a dominant share of the field, which means competitive risk comes more from specific claim overlap than from one company's portfolio blocking the whole space.
Filings peaked at 23 in 2019, then declined to 18 by 2021 and 12 by 2024, a 33% drop over that three-year window. This looks like a genuine cooling of new filing activity in the mechanism's core formulation space rather than a data artefact, since 2024 is the most recent year with a complete publication record. Filings from 2025 onward should not be read as continuing that decline, because patent publication typically lags actual filing by around 18 months, so the newest years in any dataset are always undercounted.
The claims that are hardest to avoid are structural ones describing the tablet's physical architecture — for example a low-density core combined with a semi-permeable osmotic outer coating, as in US9861585B2, or core-plus-gas-chamber constructions found in other frequently cited records. These are harder to design around than compositional claims over a specific excipient, because changing the physical construction usually changes how the tablet actually floats. Practical alternatives typically mean switching to a different buoyancy mechanism entirely — gas-generating instead of osmotic, or matrix-only instead of coated — rather than trying to narrow claim limitations within the same architecture.
The thinnest branches in the dataset are additive-manufacturing-based floating tablets (B33Y, 1.5% of records), food-format gastroretentive delivery (A23L, 1.5%), and agrochemical buoyant formulations (A01N, 1.2%), all far below the 91.9% concentration in core medicinal-preparation claims. These low-count subclasses suggest technically distinct approaches — particularly 3D-printed internal geometries engineered for buoyancy — that have not been heavily claimed yet, even though the underlying manufacturing techniques are mature in other fields. A first filing there would need to tie a specific printed structure to a measurable buoyancy or retention property to avoid reading too broadly against the existing low-density-matrix prior art.
Go past this page: query the whole gastroretentive floating tablet buoyancy control patent landscape corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company's registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.
Help us improve
Something wrong, out of date, or missing on this page? Tell us and it goes straight to the team that maintains it.
This page